Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
Noémie TrystramVered AbitbolJenny TannouryMahaut LecomteJulie AssarafGeorgia MalamutCharlotte GagnièreAmélie BarréIradj SobhaniStanislas ChaussadeAurélien AmiotPublished in: Alimentary pharmacology & therapeutics (2021)
Double switching from the originator Infliximab to CT-P13 and then to SB2 was not associated with an impairment in patient beliefs, while the effectiveness, immunogeniity and safety of anti-TNF therapy remained stable after 54 weeks of follow-up.
Keyphrases
- patients with inflammatory bowel disease
- image quality
- dual energy
- computed tomography
- contrast enhanced
- ulcerative colitis
- systematic review
- rheumatoid arthritis
- positron emission tomography
- case report
- magnetic resonance imaging
- stem cells
- mesenchymal stem cells
- bone marrow
- cell therapy
- pet ct
- replacement therapy